NZ565639A - Use of SDF-1 for the treatment and/or prevention of neurological diseases - Google Patents

Info

Publication number

NZ565639A

NZ565639A NZ565639A NZ56563906A NZ565639A NZ 565639 A NZ565639 A NZ 565639A NZ 565639 A NZ565639 A NZ 565639A NZ 56563906 A NZ56563906 A NZ 56563906A NZ 565639 A NZ565639 A NZ 565639A

Authority

NZ

New Zealand

Prior art keywords

sdf

seq

amino acid

multiple sclerosis

use according

Prior art date

2005-10-31

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 69
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title claims abstract description 62
• 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 59
• 208000025966 Neurological disease Diseases 0.000 title claims abstract description 58
• 230000002265 prevention Effects 0.000 title claims abstract description 23
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title claims abstract 18
• 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 53
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 53
• 201000001119 neuropathy Diseases 0.000 claims abstract description 37
• 230000007823 neuropathy Effects 0.000 claims abstract description 37
• 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 36
• 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 23
• 239000003814 drug Substances 0.000 claims abstract description 22
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims abstract description 21
• 208000028389 Nerve injury Diseases 0.000 claims abstract description 19
• 230000008764 nerve damage Effects 0.000 claims abstract description 19
• 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims abstract description 17
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims abstract description 17
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims abstract description 17
• 238000004519 manufacturing process Methods 0.000 claims abstract description 17
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims abstract description 17
• 229930182817 methionine Natural products 0.000 claims abstract description 16
• 230000000472 traumatic effect Effects 0.000 claims abstract description 16
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims abstract description 13
• 208000011580 syndromic disease Diseases 0.000 claims abstract description 11
• 108090000623 proteins and genes Proteins 0.000 claims description 85
• 102000004169 proteins and genes Human genes 0.000 claims description 61
• 208000014674 injury Diseases 0.000 claims description 41
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
• 150000001413 amino acids Chemical class 0.000 claims description 33
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
• 229920001184 polypeptide Polymers 0.000 claims description 29
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 22
• 210000000278 spinal cord Anatomy 0.000 claims description 20
• 150000003839 salts Chemical class 0.000 claims description 18
• 150000007523 nucleic acids Chemical class 0.000 claims description 17
• 230000008733 trauma Effects 0.000 claims description 17
• 102000014150 Interferons Human genes 0.000 claims description 16
• 108010050904 Interferons Proteins 0.000 claims description 16
• 230000037396 body weight Effects 0.000 claims description 16
• 229940079322 interferon Drugs 0.000 claims description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
• 108020004707 nucleic acids Proteins 0.000 claims description 13
• 102000039446 nucleic acids Human genes 0.000 claims description 13
• 238000006467 substitution reaction Methods 0.000 claims description 12
• 108010061299 CXCR4 Receptors Proteins 0.000 claims description 8
• 230000008499 blood brain barrier function Effects 0.000 claims description 8
• 102000012000 CXCR4 Receptors Human genes 0.000 claims description 7
• 102000003780 Clusterin Human genes 0.000 claims description 7
• 108090000197 Clusterin Proteins 0.000 claims description 7
• 102000004264 Osteopontin Human genes 0.000 claims description 7
• 108010081689 Osteopontin Proteins 0.000 claims description 7
• 208000004296 neuralgia Diseases 0.000 claims description 7
• 208000021722 neuropathic pain Diseases 0.000 claims description 7
• 210000000578 peripheral nerve Anatomy 0.000 claims description 7
• 239000013604 expression vector Substances 0.000 claims description 6
• 108060003951 Immunoglobulin Proteins 0.000 claims description 5
• 230000000295 complement effect Effects 0.000 claims description 5
• 102000018358 immunoglobulin Human genes 0.000 claims description 5
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
• 230000004927 fusion Effects 0.000 claims description 4
• 210000001218 blood-brain barrier Anatomy 0.000 claims description 3
• 238000001415 gene therapy Methods 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 69
• 235000018102 proteins Nutrition 0.000 description 55
• 241000700159 Rattus Species 0.000 description 54
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
• 239000003981 vehicle Substances 0.000 description 47
• 230000000694 effects Effects 0.000 description 45
• 230000006378 damage Effects 0.000 description 43
• 210000005036 nerve Anatomy 0.000 description 43
• 210000004556 brain Anatomy 0.000 description 40
• 108090001005 Interleukin-6 Proteins 0.000 description 39
• 102000004889 Interleukin-6 Human genes 0.000 description 39
• 210000004027 cell Anatomy 0.000 description 37
• 238000000034 method Methods 0.000 description 33
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 33
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 32
• 229960001052 streptozocin Drugs 0.000 description 32
• 241000699670 Mus sp. Species 0.000 description 30
• 201000010099 disease Diseases 0.000 description 30
• 235000001014 amino acid Nutrition 0.000 description 29
• 239000000835 fiber Substances 0.000 description 29
• 102000019034 Chemokines Human genes 0.000 description 28
• 108010012236 Chemokines Proteins 0.000 description 28
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 27
• 108010029485 Protein Isoforms Proteins 0.000 description 27
• 102000001708 Protein Isoforms Human genes 0.000 description 27
• 239000002158 endotoxin Substances 0.000 description 27
• 229920006008 lipopolysaccharide Polymers 0.000 description 27
• 230000003959 neuroinflammation Effects 0.000 description 27
• 241001465754 Metazoa Species 0.000 description 26
• 238000007920 subcutaneous administration Methods 0.000 description 24
• 208000027418 Wounds and injury Diseases 0.000 description 23
• 230000001684 chronic effect Effects 0.000 description 23
• 208000035475 disorder Diseases 0.000 description 23
• 238000012360 testing method Methods 0.000 description 22
• 230000027455 binding Effects 0.000 description 21
• 210000003497 sciatic nerve Anatomy 0.000 description 20
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 19
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 19
• 206010061218 Inflammation Diseases 0.000 description 18
• 150000001875 compounds Chemical class 0.000 description 18
• 230000002757 inflammatory effect Effects 0.000 description 18
• 230000004054 inflammatory process Effects 0.000 description 18
• 210000003205 muscle Anatomy 0.000 description 18
• 230000004770 neurodegeneration Effects 0.000 description 18
• 208000024827 Alzheimer disease Diseases 0.000 description 17
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 17
• 230000036982 action potential Effects 0.000 description 17
• 230000014509 gene expression Effects 0.000 description 17
• 210000001428 peripheral nervous system Anatomy 0.000 description 17
• 230000006870 function Effects 0.000 description 16
• 229920002683 Glycosaminoglycan Polymers 0.000 description 15
• 206010036105 Polyneuropathy Diseases 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 15
• 230000007824 polyneuropathy Effects 0.000 description 15
• 230000000750 progressive effect Effects 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
• 102100040247 Tumor necrosis factor Human genes 0.000 description 14
• 125000000539 amino acid group Chemical group 0.000 description 14
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 13
• 230000001154 acute effect Effects 0.000 description 13
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 13
• 208000024891 symptom Diseases 0.000 description 13
• 210000001130 astrocyte Anatomy 0.000 description 12
• 230000003902 lesion Effects 0.000 description 12
• 210000000265 leukocyte Anatomy 0.000 description 12
• 210000000274 microglia Anatomy 0.000 description 12
• 201000005518 mononeuropathy Diseases 0.000 description 12
• 230000003376 axonal effect Effects 0.000 description 11
• 230000003210 demyelinating effect Effects 0.000 description 11
• 201000002491 encephalomyelitis Diseases 0.000 description 11
• 239000012634 fragment Substances 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 208000015122 neurodegenerative disease Diseases 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 10
• 108090000695 Cytokines Proteins 0.000 description 10
• 208000018737 Parkinson disease Diseases 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 208000006011 Stroke Diseases 0.000 description 10
• 230000001054 cortical effect Effects 0.000 description 10
• 230000001681 protective effect Effects 0.000 description 10
• 239000013598 vector Substances 0.000 description 10
• -1 DNA or RNA Chemical class 0.000 description 9
• 208000001089 Multiple system atrophy Diseases 0.000 description 9
• 230000000875 corresponding effect Effects 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 230000007830 nerve conduction Effects 0.000 description 9
• 210000002569 neuron Anatomy 0.000 description 9
• 210000004248 oligodendroglia Anatomy 0.000 description 9
• 230000001953 sensory effect Effects 0.000 description 9
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• 238000010171 animal model Methods 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 210000003169 central nervous system Anatomy 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• 230000007850 degeneration Effects 0.000 description 8
• 102000043525 human CXCL12 Human genes 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 230000033001 locomotion Effects 0.000 description 8
• 239000011777 magnesium Substances 0.000 description 8
• 210000004126 nerve fiber Anatomy 0.000 description 8
• 230000001537 neural effect Effects 0.000 description 8
• 230000000926 neurological effect Effects 0.000 description 8
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
• 238000011084 recovery Methods 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 7
• 208000004454 Hyperalgesia Diseases 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 108010083674 Myelin Proteins Proteins 0.000 description 7
• 102000006386 Myelin Proteins Human genes 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 230000002950 deficient Effects 0.000 description 7
• 208000027866 inflammatory disease Diseases 0.000 description 7
• 210000002414 leg Anatomy 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000003387 muscular Effects 0.000 description 7
• 210000005012 myelin Anatomy 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 230000007115 recruitment Effects 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 6
• 208000023105 Huntington disease Diseases 0.000 description 6
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
• 208000016604 Lyme disease Diseases 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 206010033799 Paralysis Diseases 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 230000017531 blood circulation Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 210000003007 myelin sheath Anatomy 0.000 description 6
• 230000023105 myelination Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 108700024394 Exon Proteins 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 5
• 206010040030 Sensory loss Diseases 0.000 description 5
• 208000030886 Traumatic Brain injury Diseases 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 210000005013 brain tissue Anatomy 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 230000002490 cerebral effect Effects 0.000 description 5
• 208000026106 cerebrovascular disease Diseases 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 239000000203 mixture Substances 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000000653 nervous system Anatomy 0.000 description 5
• 210000004498 neuroglial cell Anatomy 0.000 description 5
• 230000036407 pain Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 230000035807 sensation Effects 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
• 102000009410 Chemokine receptor Human genes 0.000 description 4
• 108050000299 Chemokine receptor Proteins 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• 201000009906 Meningitis Diseases 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 230000037444 atrophy Effects 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000001124 body fluid Anatomy 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 208000029028 brain injury Diseases 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 239000007979 citrate buffer Substances 0.000 description 4
• 210000003792 cranial nerve Anatomy 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 206010014599 encephalitis Diseases 0.000 description 4
• 210000004884 grey matter Anatomy 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 210000000548 hind-foot Anatomy 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 208000028867 ischemia Diseases 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 230000007658 neurological function Effects 0.000 description 4
• 230000000324 neuroprotective effect Effects 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 208000000813 polyradiculoneuropathy Diseases 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 235000008160 pyridoxine Nutrition 0.000 description 4
• 239000011677 pyridoxine Substances 0.000 description 4
• 230000011514 reflex Effects 0.000 description 4
• 210000002027 skeletal muscle Anatomy 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• 229940011671 vitamin b6 Drugs 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 208000037157 Azotemia Diseases 0.000 description 3
• 208000035143 Bacterial infection Diseases 0.000 description 3
• 208000024806 Brain atrophy Diseases 0.000 description 3
• 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 3
• 201000010374 Down Syndrome Diseases 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 102100020997 Fractalkine Human genes 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• 206010024229 Leprosy Diseases 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 208000010428 Muscle Weakness Diseases 0.000 description 3
• 206010028289 Muscle atrophy Diseases 0.000 description 3
• 206010028372 Muscular weakness Diseases 0.000 description 3
• 206010029350 Neurotoxicity Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 241000097929 Porphyria Species 0.000 description 3
• 208000010642 Porphyrias Diseases 0.000 description 3
• 108010067787 Proteoglycans Proteins 0.000 description 3
• 102000016611 Proteoglycans Human genes 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 206010044221 Toxic encephalopathy Diseases 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 210000001642 activated microglia Anatomy 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 238000000540 analysis of variance Methods 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 208000022362 bacterial infectious disease Diseases 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000036770 blood supply Effects 0.000 description 3
• 230000006931 brain damage Effects 0.000 description 3
• 231100000874 brain damage Toxicity 0.000 description 3
• 230000003925 brain function Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000002975 chemoattractant Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000006866 deterioration Effects 0.000 description 3
• 229960003957 dexamethasone Drugs 0.000 description 3
• 206010013023 diphtheria Diseases 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 238000012120 genotypic test Methods 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 229960002897 heparin Drugs 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 239000003018 immunosuppressive agent Chemical group 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 239000007928 intraperitoneal injection Substances 0.000 description 3
• 230000005923 long-lasting effect Effects 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 208000030159 metabolic disease Diseases 0.000 description 3
• 238000007491 morphometric analysis Methods 0.000 description 3
• 201000000585 muscular atrophy Diseases 0.000 description 3
• 230000007971 neurological deficit Effects 0.000 description 3
• 231100000228 neurotoxicity Toxicity 0.000 description 3
• 230000007135 neurotoxicity Effects 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 238000011458 pharmacological treatment Methods 0.000 description 3
• 230000004850 protein–protein interaction Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 210000004116 schwann cell Anatomy 0.000 description 3
• 210000000273 spinal nerve root Anatomy 0.000 description 3
• 210000002536 stromal cell Anatomy 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 210000002435 tendon Anatomy 0.000 description 3
• 231100000167 toxic agent Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 239000003440 toxic substance Substances 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 208000009852 uremia Diseases 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 230000001457 vasomotor Effects 0.000 description 3
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010003399 Arthropod bite Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 102000001902 CC Chemokines Human genes 0.000 description 2
• 108010040471 CC Chemokines Proteins 0.000 description 2
• 108050006947 CXC Chemokine Proteins 0.000 description 2
• 102000019388 CXC chemokine Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 208000014912 Central Nervous System Infections Diseases 0.000 description 2
• 206010008190 Cerebrovascular accident Diseases 0.000 description 2
• 108010078239 Chemokine CX3CL1 Proteins 0.000 description 2
• 208000018652 Closed Head injury Diseases 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 206010010071 Coma Diseases 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• 238000001061 Dunnett's test Methods 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 229920002971 Heparan sulfate Polymers 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 2
• OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 206010033892 Paraplegia Diseases 0.000 description 2
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• 206010039966 Senile dementia Diseases 0.000 description 2
• IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 2
• KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 208000004374 Tick Bites Diseases 0.000 description 2
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 208000003056 Vitamin B6 deficiency Diseases 0.000 description 2
• 206010073696 Wallerian degeneration Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 238000011953 bioanalysis Methods 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000036760 body temperature Effects 0.000 description 2
• 239000008366 buffered solution Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000006041 cell recruitment Effects 0.000 description 2
• 210000004720 cerebrum Anatomy 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000009519 contusion Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 108010004073 cysteinylcysteine Proteins 0.000 description 2
• 229960000860 dapsone Drugs 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 230000035987 intoxication Effects 0.000 description 2
• 231100000566 intoxication Toxicity 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 229960003350 isoniazid Drugs 0.000 description 2
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• 208000036546 leukodystrophy Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 235000018977 lysine Nutrition 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000028161 membrane depolarization Effects 0.000 description 2
• 210000002418 meninge Anatomy 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 108010085203 methionylmethionine Proteins 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 210000000461 neuroepithelial cell Anatomy 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 235000018343 nutrient deficiency Nutrition 0.000 description 2
• VBPVZDFRUFVPDV-UHFFFAOYSA-N o-pentylhydroxylamine Chemical compound CCCCCON VBPVZDFRUFVPDV-UHFFFAOYSA-N 0.000 description 2
• 230000003565 oculomotor Effects 0.000 description 2
• 238000006384 oligomerization reaction Methods 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 208000021090 palsy Diseases 0.000 description 2
• 208000035824 paresthesia Diseases 0.000 description 2
• 210000003200 peritoneal cavity Anatomy 0.000 description 2
• 102000013415 peroxidase activity proteins Human genes 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 239000008055 phosphate buffer solution Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000008092 positive effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000000272 proprioceptive effect Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 230000002336 repolarization Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 238000003118 sandwich ELISA Methods 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
• 238000007390 skin biopsy Methods 0.000 description 2
• 210000003625 skull Anatomy 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 239000010936 titanium Substances 0.000 description 2
• 229910052719 titanium Inorganic materials 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000009529 traumatic brain injury Effects 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 230000008734 wallerian degeneration Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 210000004885 white matter Anatomy 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• 101150029062 15 gene Proteins 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 229940124321 AIDS medicine Drugs 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 102000016912 Aldehyde Reductase Human genes 0.000 description 1
• 108010053754 Aldehyde reductase Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
• APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
• BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
• FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 1
• ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 1
• FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
• XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 208000002381 Brain Hypoxia Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• 108010075254 C-Peptide Proteins 0.000 description 1
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
• 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
• 238000011749 CBA mouse Methods 0.000 description 1
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 206010008132 Cerebral thrombosis Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 description 1
• 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
• 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
• GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 208000019736 Cranial nerve disease Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
• KPENUVBHAKRDQR-GUBZILKMSA-N Cys-His-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPENUVBHAKRDQR-GUBZILKMSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 102220605444 DNA-(apurinic or apyrimidinic site) endonuclease_K24A_mutation Human genes 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
• 208000000202 Diffuse Axonal Injury Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 102100029951 Estrogen receptor beta Human genes 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 208000034347 Faecal incontinence Diseases 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 208000015220 Febrile disease Diseases 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
• XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 1
• CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 description 1
• MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
• 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 description 1
• 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
• 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000005420 Hyperemesis Gravidarum Diseases 0.000 description 1
• 206010021135 Hypovitaminosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100026236 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
• 208000027747 Kennedy disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 description 1
• MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
• UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
• UIIMIKFNIYPDJF-WDSOQIARSA-N Leu-Trp-Met Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 UIIMIKFNIYPDJF-WDSOQIARSA-N 0.000 description 1
• WPIKRJDRQVFRHP-TUSQITKMSA-N Leu-Trp-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O WPIKRJDRQVFRHP-TUSQITKMSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 1
• OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 238000000719 MTS assay Methods 0.000 description 1
• 231100000070 MTS assay Toxicity 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
• VQILILSLEFDECU-GUBZILKMSA-N Met-Pro-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O VQILILSLEFDECU-GUBZILKMSA-N 0.000 description 1
• XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 1
• UYDDNEYNGGSTDW-OYDLWJJNSA-N Met-Trp-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N UYDDNEYNGGSTDW-OYDLWJJNSA-N 0.000 description 1
• 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
• 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
• 101000617124 Mus musculus Stromal cell-derived factor 1 Proteins 0.000 description 1
• 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 101150008132 NDE1 gene Proteins 0.000 description 1
• 238000011785 NMRI mouse Methods 0.000 description 1
• 208000006079 Near drowning Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 206010031127 Orthostatic hypotension Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000002774 Paraproteinemias Diseases 0.000 description 1
• 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
• FRMKIPSIZSFTTE-HJOGWXRNSA-N Phe-Tyr-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FRMKIPSIZSFTTE-HJOGWXRNSA-N 0.000 description 1
• IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
• GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010039203 Road traffic accident Diseases 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 206010040021 Sensory abnormalities Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000020339 Spinal injury Diseases 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 102220537443 Testin_K25A_mutation Human genes 0.000 description 1
• 102220537421 Testin_K27A_mutation Human genes 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 102220484179 Thioredoxin domain-containing protein 8_K28A_mutation Human genes 0.000 description 1
• TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
• NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
• ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
• AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• 102220477041 Zinc fingers and homeoboxes protein 1, isoform 2_H25A_mutation Human genes 0.000 description 1
• 102220477042 Zinc fingers and homeoboxes protein 1, isoform 2_H26A_mutation Human genes 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 210000001056 activated astrocyte Anatomy 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 108010087924 alanylproline Proteins 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940030225 antihemorrhagics Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 230000006470 autoimmune attack Effects 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 230000007844 axonal damage Effects 0.000 description 1
• 230000007845 axonopathy Effects 0.000 description 1
• 229960002319 barbital Drugs 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 208000002894 beriberi Diseases 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 230000001612 cachectic effect Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000021617 central nervous system development Effects 0.000 description 1
• 208000025222 central nervous system infectious disease Diseases 0.000 description 1
• 210000000782 cerebellar granule cell Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 210000002932 cholinergic neuron Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000000749 co-immunoprecipitation Methods 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229960002656 didanosine Drugs 0.000 description 1
• 230000009521 diffuse axonal injury Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000001206 effect on leukocytes Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 238000002567 electromyography Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 238000007667 floating Methods 0.000 description 1
• 238000002795 fluorescence method Methods 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 210000000609 ganglia Anatomy 0.000 description 1
• 238000010413 gardening Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 125000003827 glycol group Chemical group 0.000 description 1
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000000025 haemostatic effect Effects 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
• 229960002456 hexobarbital Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 108010025306 histidylleucine Proteins 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 102000044493 human CDCA4 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 201000010930 hyperostosis Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000037451 immune surveillance Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108010054155 lysyllysine Proteins 0.000 description 1
• GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
• 239000004137 magnesium phosphate Substances 0.000 description 1
• 229960002261 magnesium phosphate Drugs 0.000 description 1
• 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
• 235000010994 magnesium phosphates Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 201000011475 meningoencephalitis Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000006371 metabolic abnormality Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000006724 microglial activation Effects 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 208000015015 neurological dysfunction Diseases 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000017511 neuron migration Effects 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 230000007996 neuronal plasticity Effects 0.000 description 1
• 230000005015 neuronal process Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000037324 pain perception Effects 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 229940055726 pantothenic acid Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000008289 pathophysiological mechanism Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
• 108010043655 penetratin Proteins 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 238000001558 permutation test Methods 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
• 230000036544 posture Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000009023 proprioceptive sensation Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 108700043101 rat CXCL12 Proteins 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 208000037921 secondary disease Diseases 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000036362 sensorimotor function Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000031998 transcytosis Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 208000030401 vitamin deficiency disease Diseases 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1